Journal of neurosurgery · 1987 · 160 citations · 11 references
MedicineEndocrinologyPathologyEndocrine OncologyNeoplasiaTumor PathologyEndocrine Tumor DiagnosisEndocrine Tumor PathologyEndocrine TumorsHormone-secreting TumorsPituitary DisordersPituitary TumorsBromocriptine TreatmentGrowth FractionPituitary Tumor Growth PatternsPituitary Tumor HistopathologyPituitary Tumor ImmunohistochemistryPituitary Tumor PathologyProlactin-secreting AdenomasTumor Growth Rate
The immunohistological detection of a proliferation-associated nuclear antigen by the monoclonal antibody Ki-67 allows the determination of the growth fraction in human cell populations. In this study, biopsy specimens of 31 pituitary adenomas representing all major endocrine types were examined. All adenomas contained proliferating cells and the percentage of nuclei that were immunoreactive to Ki-67 ranged from 0.1% to 3.7%. Low values (0.1% to 1.0%) were present in 11 endocrine-inactive adenomas and higher values (1.1% to 1.5%) were found in six acromegalic patients. The percentages of Ki-67-positive cells in 12 prolactinomas and two adenomas from patients with Cushing's disease covered the entire range (0.1% to 3.7%). Preoperative bromocriptine treatment of prolactinomas did not influence Ki-67 expression. Invasive adenomas, as determined by preoperative computerized tomography, surgical observation, and histological examination of the sella dura demonstrated significantly higher Ki-67 values (average 1.15%) than noninvasive adenomas (average 0.60%). Determination of the incidence of proliferating cells by Ki-67 immunoreactivity represents a new tool for intraoperative quantitative assessment of tumor growth characteristics and may aid in the planning of adjuvant therapy and estimation of prognosis.
11
G. M. Addison · The Lancet · 1974 · 336 citations
Ivan Ćirić · Surgical Neurology · 1981 · 154 citations